# FDA staff question peptides backed by Kennedy ahead of advisory panel review - reuters.com

*Источник: reuters.com*
*Дата: 2026-07-01*
*Язык: en*

<a href="https://news.google.com/rss/articles/CBMi1gFBVV95cUxOS2t3aEwtTU11ZGtkSWdCTHBDODlKLUZ5Z095amFiSG9CYTkxcW01cXo3aVpWS096ZnM0S0lHclJYemhQbVpRTFY3bGRYMzhmUEZ1cmJtSG4xbngtZXpGLWh6YTVxZVlFNWlqS0tGOEowVkpGUWtTTmhCamZhNzM0aFVSOVRtcjJ5WUdOWmxtVVcxeWFlcklZNHdiS0lWczVXUFUtcGVBLUZjOUowTG9OZU9SWC1HNUt5enZ1Uk8xN3BpNldwdENIaDdobmVvSllpR3Y0UnpR?oc=5" target="_blank">FDA staff question peptides backed by Kennedy ahead of advisory panel review</a>&nbsp;&nbsp;<font color="#6f6f6f">reuters.com</font>

[Оригинал](https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-staff-highlights-peptide-risks-says-little-evidence-benefits-2026-06-30/)